Featured Product
This Week in Quality Digest Live
FDA Compliance Features
Del Williams
Mitigate risk, prevent safety issues by utilizing closed conveyor systems designed with sanitation in mind
Dirk Dusharme @ Quality Digest
Companies say they plan to pull some or all of their devices
Dirk Dusharme @ Quality Digest
First step, migrate your QMS to a cloud-based electronic quality management system
Jill Roberts
Another way to know what’s too old to eat
Patricia Santos-Serrao
Four pharma quality trends

More Features

FDA Compliance News
Showcasing tech, solutions, and services at Gulfood Manufacturing 2022
Easy, reliable leak testing with methylene blue
Now is not the time to skip critical factory audits and supply chain assessments
Google Docs collaboration, more efficient management of quality deviations
Delivers time, cost, and efficiency savings while streamlining compliance activity
First trial module of learning tool focuses on ISO 9001 and is available now
Free education source for global medical device community
Good quality is adding an average of 11 percent to organizations’ revenue growth
Further enhances change management capabilities

More News

Michael Causey

FDA Compliance

Medical Device CEO Laments ‘Anti-Industry’ FDA Culture

Is the agency stifling medical innovation?

Published: Wednesday, April 18, 2012 - 10:16

While calling it one of the more “egregious” examples he’s seen or heard about, Fisher Wallace Labs (FWL) CEO Chip Fisher said the Food and Drug Administration’s (FDA) attempt to “force its own agenda” over dissenting science or how its own advisory boards vote on medical device classification is just part of a broader “systemic” problem with some at the agency.

As reported earlier in Medical Device Daily and elsewhere, an FDA advisory committee hearing in February for cranial electrotherapy stimulator (CES) medical devices was flawed, in part FWL alleges, because the FDA violated its own rules in running the hearing. FWL filed a March 9, 2012, citizen’s petition challenging the FDA’s proposed classification of CES devices as high-risk or Class III devices.

Kelly Roman, FWL’s vice president, said he’s “heartened,” however, that the FDA has said publicly that it will discuss the situation directly with FWL. “The fact that they responded at all” is unusual for the agency in a case like this, and Roman believes it bodes well for FWL’s desire to have its CES keep its Class I designation.

But Fisher worries that this kind of FDA activity is stifling medical innovation, especially for smaller companies that may not be able to afford a long and drawn-out battle like this with the agency.

“I think there’s a growing culture of anti-industry” at the FDA, Fisher says. Specifically, he criticized a faction at the FDA for “picking apart” and using aspects of research to prove the point it wanted to prove, but not always considering the full body of research that might support another position.

Roman doesn’t expect to hear from the FDA for many months and has gotten no official timetable from the agency. “We appreciate that the FDA is a big slow-moving ship,” he notes.

For a glimpse at some of the February hearing that troubled FWL, click here.

This article first appeared in the April 11, 2012, edition of the AssurX blog.


About The Author

Michael Causey’s picture

Michael Causey

James Michael Causey’s been a journalist since he started his own neighborhood newspaper in the 1970s. In addition to quizzing FDA officials for the past 10+ years, he’s also interviewed political satirist Art Buchwald, FCC Chairman Reed Hundt, SEC Chairwoman Mary Schapiro, and is the past president of the Washington Independent Writers. Causey is the editor and publisher of eDataIntegrityReport.com and is a contributing writer on the AssurXblog.